Lysosomes serve dual roles in cancer metabolism, executing catabolic programs (i.e. autophagy and macropinocytosis), while promoting mTORC1-dependent anabolism.
need to develop more potent lysosomal inhibitors and to define the molecular target responsible for lysosomal inhibition.
We previously reported Lys05, a dimeric chloroquine (CQ) that is 10-fold more potent than monomeric CQ derivatives (11) . Given the recent appreciation of the lysosomal regulation of mTORC1, we hypothesized that more potent and specific inhibitors of the lysosome could concurrently inhibit lysosomal catabolism and mTORC1 signaling. Towards this goal, we modified the Lys05 structure, ultimately yielding a series of potent dimeric quinacrines (DQs). We find that methylation of the central nitrogen of the linker impacts DQ subcellular localization and enhances DQ function against autophagy. This approach has led to the identification of a class of compounds that that can be targeted specifically to the lysosome. Using these more potent and lysosome-specific inhibitors, we have identified the molecular target of DQ as palmitoylprotein thioesterase 1 (PPT1), resulting in the impairment of mTOR signaling via disruption of the interaction between mTORC1 and its master activator Rheb, even in the setting of amino acid-replete medium. The concurrent inhibition of mTORC1 and lysosomal catabolism, one of the key resistance mechanisms to existing mTOR inhibitors, leads to a more complete abrogation of protein translation and anti-cancer activity relative to what is achievable with allosteric or catalytic mTORC1 inhibitors. Our findings reveal an unanticipated role of PPT1 in regulating both autophagy and mTORC1 localization and activity in cancer.
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Results

DQ has superior anticancer efficacy amongst dimeric antimalarials.
In an effort to improve the activity of Lys05, we extended the triamine linker of Lys05 using the naturally occurring triamine, spermidine. The anti-cancer activity of the resulting compound, DC340, the name of which was derived as described below, was assessed in BRAF-mutant melanoma and KRAS-mutant pancreatic cancer cell lines, as cancers driven by these oncogenes depend on autophagy/lysosome function (12, 13) .
DC340 inhibited the growth of a panel of melanoma and pancreatic cancer cell lines significantly better than Lys05 ( Figure 1A and 1B) . We next developed a series of dimeric compounds linked by the spermidine linker, whereby the 7-chloroquinoline heterocycles of CQ were replaced with the heterocyclic rings present in other antimalarials, such as primaquine (PQ), mefloquine (MQ) and QN (quinacrine, Figure   1A ). We describe these resulting novel structures as DC (dimeric CQ), DM (dimeric MQ), DP (dimeric PQ) or DQ (dimeric QN), followed by three digits (m, n, R) where m and n signify the number of carbons to the left and right of the central nitrogen of the triamine linker, respectively, and the R signifies whether the central nitrogen of the linker is methylated (1) or not (0) ( Figure 1A ). Anti-proliferative activity was improved between 3-10 fold for each dimeric compound that contained CQ, MQ, or PQ, relative to its monomeric parent. In contrast, dimerization of QN resulted in ≥ 60-fold improvement in anti-proliferative activity relative to monomeric QN ( Figure 1C ).
We next generated a focused library of DQs with triamine linkers of increasing length, ranging from 2-11 carbons between the 9-aminoacridine and the central nitrogen Figure S1A ). While, DQ221, the acridine dimer with the same linker as Lys05 (DC221 using this nomenclature system), showed the same potency as its corresponding monomer with no benefit from dimerization, a clear relationship between linker length and potency emerged amongst the DQs with increasing linker length, whereby DQs with 3-6 carbons between linker nitrogens possessed significant anti-proliferative potency. Further extension of the distance between the two QN heterocycles resulted in incrementally decreased anti-proliferative activity ( Figure 1D , Supplemental Figure S1A ). Pharmacological agents that specifically inhibit autophagy, such as Spautin-1, which promotes degradation of Beclin (14) , and SBI-0206965 (SBI), an unc-like kinase 1 (ULK1) inhibitor (14, 15) , exhibited significantly less potency relative to DQs ( Figure 1D , Supplemental Figure S1A ). The compounds in the series DQ330-DQ661 produce significantly greater long-term growth suppression compared to monomeric QN and DQ221 (Supplemental Figure S1B ). Unlike Spautin-1 and SBI, which did not induce appreciable levels of apoptosis, the majority of DQs trigger significantly greater levels of apoptosis, which directly correlates with increasing linker length, relative to monomeric QN ( Figure 1E ).
Central nitrogen methylation directs subcellular localization of DQs.
We next interrogated the specificity of DQs as lysosomal inhibitors, as the parent monomer, QN, both binds to DNA in the nucleus and accumulates in the lysosome (16 The inherent fluorescence of DQs was exploited to study their subcellular localization.
The most potent longer-linked DQs (DQ550, DQ551, DQ660, DQ661) fluoresce in both the red and green channels, under both neutral (pH = 7) and acidic (pH = 4) conditions ( Figure 2A ). Under neutral conditions, methylated DQs demonstrated increased green fluorescence compared to unmethylated DQs. However, there were no significant differences in red fluorescence observed between unmethylated and methylated DQs.
Acidic conditions led to partial quenching of green fluorescence, but had minimal effects on red fluorescence in both methylated (DQ551, DQ661) and unmethylated (DQ550, DQ660) DQs. These findings indicate that red fluorescence is more effective to assess lysosomal localization of these compounds. Surprisingly, each unmethylated DQ Figure S2B ). To rule out the possibility that the addition of a methyl group to the central nitrogen was simply increasing the basicity of the DQ, thereby trapping the methylated derivatives in the acidic lysosome, the pK a 's of each DQ were calculated (Supplemental Table 1 ). This analysis demonstrated that the pK a of each pair of methylated and unmethylated DQ did not differ significantly, and therefore differential basicity could not account for the difference in subcellular localization. marker of completed autophagosomes (17) . Increasing DQ linker length was associated with increasing LC3II/LC3I ratios ( Figure 2C ), reflecting an accumulation of AVs.
Interestingly, there was also a relationship between central nitrogen methylation and LC3II/LC3I ratios, in which compounds with central nitrogen methylation (DQXX1) had a significantly higher LC3II/LC3I ratio relative to their unmethylated (DQXX0) counterparts. Due to the inherent fluorescence of QN, spectral overlap with mCherry-eGFP-LC3 expressing cells (18) prevented the use of this approach to characterize autophagic flux. The effects of these compounds on autophagic flux were therefore determined by a bafilomycin (baf) clamp experiment (19) . Treatment with DQs lacking central nitrogen methylation (DQXX0) resulted in a further increase in the LC3II/LC3I ratio in bafilomycin (baf)-treated cells compared with control cells, confirming that all DQs lacking a centrally methylated nitrogen (DQXX0) significantly increase autophagic flux ( Figure 2D ). In contrast, every DQ with central nitrogen methylation (DQXX1) did not demonstrate an increase in LC3II/LC3I ratio in baf-treated cells compared to control ( Figure 2D ). This difference in autophagy modulation between unmethylated and methylated DQs was also evidenced by unmethylated DQs producing striking degradation of the autophagy substrates p62 and NBR1, whereas treatment with methylated DQs did not ( Figure 2E Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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DQs cause either significant DNA damage or lysosomal membrane permeabilization depending on the central nitrogen methylation status.
We next determined whether DQs cause DNA damage, since QN is known to intercalate DNA (20) . A striking relationship between nitrogen methylation and DNA damage emerged, whereby unmethylated DQs induced significantly greater levels of DNA damage relative to their methylated counterparts ( Figure 3A ). Furthermore, the difference in DNA damage induced by unmethylated DQs versus the corresponding methylated analogs increased with increasing linker length for each pair of compounds.
The integrity of the lysosomal membrane was interrogated by detection of lectin galactoside binding soluble 3 (LGALS3)/galectin-3 localization, which was recently demonstrated to rapidly translocate to damaged lysosomes (21) . When lysosomes are healthy, galectin-3 is uniformly dispersed throughout the cell. However, when the lysosome is damaged, galectin-3 rapidly localizes to the site of damaged lysosomes, appearing as puncta. Only methylated DQs (DQXX1) caused lysosomal membrane permeabilization (LMP), as seen by the formation of galectin-3 + puncta ( Figure 3B ). The differential ability to induce LMP was further demonstrated by the observation of mature cathepsin D in the extra-lysosomal fraction of cells treated with DQ661 ( Figure 3C ). of DQ661, treated cells were assayed for >290 proteins or phospho-proteins spanning key signaling programs commonly perturbed in cancer cells using reverse phase protein arrays (RPPA). The proteins most significantly and reproducibly inhibited by DQ661 were downstream of mTORC1 signaling ( Figure 3D , Supplemental Figure S3A ). These included reduced phosphorylation of PRAS40, p70S6K, S6, and 4E-BP1.
Immunoblotting confirmed the RPPA results, i.e., the ability of DQ661 to inhibit autophagy and mTORC1 activity, and to induce apoptosis in BRAFV600E, NRASQ61R, and BRAF-WT/NRAS-WT melanoma cell lines ( Figure 3E ). To understand the kinetics of pathway inhibition, immunoblotting revealed that mTORC1 activity was inhibited within 30 minutes of treatment with DQ661, before appreciable accumulation of AVs was observed, as seen by LC3 lipidation ( Figure 3F ). Autophagy modulation and dephosphorylation of a number of mTOR target substrates was sustained even at the 24-hour timepoint. Cleavage of caspase 7 did not occur until mTORC1 and autophagy were both significantly inhibited. A kinetic analysis of LMP induction was also performed, revealing LMP does not occur until 2-4 hours after treatment with DQ661, suggesting the rapid mTORC1 inhibition associated with DQ661 is independent of LMP ( Figure 3G ). Further, Leu-Leu methyl ester hydrobromide (LloMe), a prototypical lysosomal membrane permeabilizing agent, did not inhibit mTORC1 activity at the 30minute timepoint when LloMe-induced LMP is clearly evident, demonstrating that DQ661-induced LMP is not responsible for mTOR inhibition (Supplemental Figure S3B ).
To determine whether the anti-mTORC1 activity of DQ661 could be observed with other agents that impair lysosomal deacidification, produce LMP, or inhibit lysosomal enzymes, A375P cells were treated with either amino-acid/serum starvation, Figure 3H ). Immunoblotting confirmed DQ661 inhibits mTORC1 activity to a similar level as serum starvation, and to a greater extent than any other lysosomal agent tested. PET inhibited S6K phosphorylation, but both PES and PET treatment led to the hyperphosphorylation of 4E-BP1. Baf had minimal effects on phospho-S6K, and produced hyper-phosphorylation of 4E-BP1. DQ661 had the greatest ability to inhibit autophagy amongst the entire panel of lysosomal inhibitors, as seen by the greatest accumulation of LC3II/LC3I ratio. At the doses and timepoints tested, DQ661 appears to be unique in its ability to inhibit both mTORC1 signaling and autophagy ( Figure 3H ). In contrast to these effects observed with DQ661, RPPA data and Western blot analysis demonstrated that neither QC nor DQ660 had a significant impact on mTORC1 signaling at equimolar doses (Supplemental Figure S3A and S3C).
MTORC1 inhibition not only upregulates autophagy, but also macropinocytosis, a process by which nutrient-limited, Ras-driven cancer cells endocytose, envelop extracellular protein, and release AAs through lysosome-mediated degradation, paradoxically fueling growth of cancer cells (24) . We next asked whether or not DQ661 would increase lysosomal catabolism of extracellular proteins since it inhibits mTORC1.
We confirmed that DQ661 blocked autophagy and mTOR in G43 mouse pancreatic cancer cells (Supplemental Figure S3D Figure 3E ). Further, torin-1 significantly increased the proliferation of glutamine-limited G43 cells supplemented with 2% albumin, relative to cells grown in low glutamine with 2% albumin treated with vehicle control (Supplemental Figure 3F ). DQ661 decreased the proliferation of G43 cells to the levels observed by cells cultured in low glutamine in the absence of 2% albumin.
To directly measure the effect of DQ661 on catabolism of extracellular protein by pancreatic cells, we devised an isotope tracer-based method to monitor protein scavenging. This method enables the separate quantification of (i) AAs added to the medium as monomers and (ii) AAs derived from degradation of extracellular protein taken up by macropinocytosis. Another cell line derived from a KPC mouse tumor, KRPC-A, which is capable of robust proliferation despite AA-deficiency in BSAsupplemented medium, was cultured in medium -containing fully 13 C-labeled essential AAs for 5 doublings, such that intracellular protein and AAs in these cells was isotopically labeled. These cells were then switched to AA-free medium containing 50 g/L BSA. Under these conditions, cells can substitute AA monomers with scavenged extracellular protein, but because BSA contains unequal levels of AAs relative to their cellular requirements, serum protein catabolism produces some of these AAs in excess of these requirements and secretes them into the medium, providing a quantitative read-out for protein scavenging rate. Using this assay, we observe that DQ661 significantly inhibits protein scavenging in a dose-dependent fashion (Supplemental Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Palmitoyl-Protein Thioesterase 1 (PPT1) is a molecular target of DQ661.
Given that LMP did not explain the mTOR inhibition observed with DQ661, we leveraged the increased potency and lysosomal localization of DQ661 to perform an in situ chemical pulldown experiment, in order to find the putative molecular target of DQ661 within the lysosome ( Figure 4A ). A photoprobe consisting of the DQ661 warhead attached to benzophenone (as a photoaffinity label), which was in turn covalently linked to desthiobiotin was synthesized ( Figure 4B ; see Methods for chemical strategy). Treatment of A375P cells with the DQ661 photoprobe produced accumulation of LC3II and decreased phosphorylation of mTOR substrates in A375P cells, demonstrating that the photoprobe was cell-permeable, localized to the lysosome, and retained activity ( Figure 4C ). Next A375P cells were treated with the DQ661 photoprobe with or without UV irradiation, and with or without competition with an excess of free DQ661 ligand immediately prior to UV irradiation. Cell lysis was followed by pulldown with neutravidin beads, and elution with biotin. Eluents were subjected to proteomic analysis (see Methods). Candidate protein targets were identified using the criteria of proteins that had >10-fold intensity ratios of +UV/-UV and -competition/+competition samples ( Figure 4D ). Of these 15 proteins, cathepsin D and PPT1 had the highest signal intensity for the +UV sample. Unlike cathepsin D, however, treatment with DQ661 competition completely abrogated the ability of the photolabel probe to pulldown PPT1
Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/2159-8290.CD-17-0741 as detected by MS. Immunoblotting against PPT1 in a separate experiment using the DQ661-photoprobe and 10X concentration of free DQ661 ligand as competition confirmed that the DQ661-photoprobe specifically bound to, and could be UVconjugated to PPT1 in cells (Supplemental Figure S4A ). Cathepsin D enzymatic activity was not significantly impaired in cell lysates from A375P cells treated with vehicle, DQ660 and DQ661 ( Figure 4E ). In contrast DQ661, but not DQ660 significantly impaired PPT1 enzymatic activity in cells ( Figure 4F ). The inability to inhibit cathepsin D enzymatic activity demonstrates the selectivity of DQ661 for PPT1, further supporting a specific rather than generic mechanism of action for DQ661 in the lysosome. Finally, differential scanning calorimetry (DSC) of recombinant PPT1 protein in the absence or presence of a 4-fold molar excess of DQ661 revealed protein melting temperatures of 67.16 and 64.60 °C, respectively ( Figure 4G ). This statistically significant difference of >2.5 °C in protein melting temperature, as a function of added DQ661, is consistent with direct DQ661 binding to PPT1.
PPT1 is the only lysosomal enzyme that cleaves thioester bonds from palmitoylated proteins, liberating these proteins from membranes to facilitate proteolysis. An acyl-biotinyl exchange assay to measure protein palmitoylation demonstrated that accumulation of palmitoylated proteins occurred as early as 30 minutes and was sustained after 2 hours of treatment with DQ661 (Supplemental Figure   S4B ). As proof of principle, the palmitoylated form of the prototypically palmitoylated protein CD44 accumulated after 30 minutes of DQ661 treatment ( Figure 4H ). SiRNA knockdown of PPT1 phenocopied DQ661 effects, as evidenced by accumulation of lipidated LC3 and p62, the abrogation of S6 phosphorylation, the inhibition of cellular Figure S4F ). Importantly, co-treatment of melanoma cells with DQ661 and the thioesterase mimetic N-(tert-butyl) hydroxylamine (NtBuHA) partially rescued mTORC1 signaling and autophagy levels ( Figure 4J ). SiRNA knockdown of PPT1 also partially blunted the ability of DQ661 to inhibit mTORC1 and autophagy (Supplemental Figure S4G ). These results further demonstrate the biological activity of DQ661 is mediated through inhibition of PPT1-dependent depalmitoylation of palmitoylated proteins.
DQ661 ejects mTOR from the lysosome membrane, disrupting mTORC1-Rheb interactions.
We hypothesized that PPT1 inhibition by DQ661 could lead to mTOR inhibition through an "inside out" signaling pathway connecting V-ATPase and Ragulator interactions. Recently the regulation of V-ATPase localization by PPT1 was described in neurons (27) . The amino acid-dependent physical interaction between vATPase and the Ragulator complex facilitates the lysosomal recruitment of mTORC1 by Rag GTPases (28) . This recruitment to the lysosome surface is critical for mTOR-Rheb interaction, allowing Rheb to phosphorylate and activate mTOR ( Figure 5A ( Figure 5B ). The physical interaction between subunit V1A (ATP6V1A) and the Ragulator component p18 was also disrupted by DQ661 as seen by proximity ligation assay (PLA) ( Figure 5C ). Immunofluorescence microscopy revealed that p18 colocalization with lysosomes was not impacted by DQ661 ( Figure 5D ). In contrast, DQ661 treatment significantly displaced RagC ( Figure 5E ) and mTORC1 ( Figure 5F) from the lysosomal surface. Immunoblotting of lysosome fractions taken from A375P cells treated with vehicle or DQ661 further corroborated the DQ661-induced displacement of RagC and mTOR from the lysosome and into the extralysosome fraction ( Figure 5G ). In addition to displacement, DQ661 also breaks the physical interaction between Rag GTPases and mTOR, as seen by PLA ( Figure 5H ) and immunoprecipitation of RagB in cells expressing FLAG-RagB, followed by immunoblotting for mTOR ( Figure 5I ). In contrast, neither rapamycin nor torin-1 could displace mTOR from the lysosome (Supplemental Figure S5A ). As Rheb is the master activator of mTORC1, we next interrogated whether DQ661, existing lysosome-targeting agents or existing mTORC1 inhibitors could impact the physical interaction between mTORC1 and Rheb. Neither rapamycin nor torin-1 was able to disrupt the physical interaction of mTOR and Rheb, as seen by PLA ( Figure 5J ). Similarly, while neither baf nor the LMP-inducer siramesine disrupted the mTOR-Rheb interaction, which is critical for mTORC1 growth signaling, this interaction was completely disrupted by DQ661 ( Figure 5J ). The unique ability of DQ661 to disrupt the mTOR-Rheb interaction is therefore not shared by allosteric or catalytic inhibitors of mTORC1, nor by other prototypical lysosomally directed cationic amphiphilic drugs (CADs). Next, incubation of cells with O-propargyl-puromycin followed by click chemistry-enabled attachment of a fluorophore was used to compare the effects of mTOR and lysosomal inhibitors on de novo protein translation (29) . Catalytic inhibition of mTORC1 decreased protein translation to a significantly greater degree than allosteric inhibition of mTORC1.
Meanwhile, lysosomal inhibition alone with baf had no effect on protein translation. In contrast, concurrent inhibition of mTORC1 and lysosomal catabolism with DQ661 was the only approach that produced near complete inhibition of protein translation (Supplemental Figure S5B ).
We observed striking differences in the anti-proliferative activity of catalytic/allosteric mTOR inhibitors compared to DQ661. While torin-1 displays significantly greater anti-proliferative activity relative to rapamycin, the growth impairment reaches a plateau at 1 μM whereby a residual population of cancer cells persists despite increasing dosages (Supplemental Figure S5C ). In contrast, DQ661 (≥ 1 μM) treatment completely inhibited viability of cancer cells with a variety of genotypes and therapy resistance profiles (Supplemental Figure S5C ). Importantly, HDSF treatment phenocopied DQ661-mediated displacement of V0A1, V1A, and mTOR from membranes ( Figure 5K ). Further, siPPT1 also displaced V0A1, V1A and mTOR ( Figure   5L ), corroborating the necessity of PPT1 for the proper lysosomal localization of vATPase components and mTOR. NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. After 1-2 weeks, tumors were palpable and mice were treated intraperitoneally (i.p.) with vehicle control (water), QN, DQ660 or DQ661 (8 mg/kg) ( Figure 6A ). QN had no significant effect on tumor growth compared to vehicle control. In contrast, DQ660 treatment resulted in a modest growth impairment of tumors compared to control or QN treated tumors. DQ661 inhibited tumor growth to a significantly greater extent than DQ660, despite differing in structure by only one methyl group. Further, DQ661 was the only compound to produce a nearly 0% growth rate ( Figure 6B ). Immunohistochemistry of tumor slides revealed the presence of γH2AX only in the DQ660-treated mice ( Figure 6C ). Electron microscopy demonstrated DQ661 alone produced visible accumulation of AVs in tumor cells ( Figure 6D ). At the 8 mg/kg dose, however, DQ661 caused weight loss greater than 10%, and by day 7 all mice were euthanized due to lethargy and bowel distension (Supplemental Figure S6A ).
In vivo lysosomal inhibition and anti-tumor activity of DQ661 in a melanoma
Histological analysis of the intestines demonstrated Paneth cell dysfunction only in DQ661-treated mice, similar to that observed in mice treated with the highest doses of Lys05 (11) (Supplemental Figure S6B ). Therefore, another 1205Lu xenograft experiment was performed in which mice were treated with vehicle control (water) or DQ661 4 mg/kg i.p. daily for a period of 14 days. Treatment with DQ661 resulted in a significant reduction in tumor volume compared to control mice without significantly affecting mouse weight ( Figure 6E , Supplemental Figure S6C ). Mice treated with 4 mg/kg DQ661 showed significantly slower rates of tumor growth ( Figure 6F ). Evidence of in vivo mTORC1 and autophagy inhibition was observed through immunoblotting of lysate from treated tumors ( Figure 6G ). To ensure the effects of DQ661 were not due to a predisposition of 1205Lu cells to mTOR or autophagy inhibition, genetic knockdown with siRNA against ATG5 or mTOR was performed and no significant impact on viability was observed (Supplemental Figure S6D and S6E) . In vivo evidence of DQ661-induced disruption of the mTOR-Rheb interaction was demonstrated by PLA ( Figure 6H ). imipramine and amitriptyline all have been shown to induce autophagy and have no effect on mTOR signaling (39) (40) (41) (42) . Our study demonstrates that incorporating a specific structural motif (central nitrogen methylation of a triamine linker) in a dimeric compound can enhance lysosomal localization and increase the specificity of CADs as antilysosomal agents. Since the unmethylated compounds tested (DQ330, DQ440, DQ550 and DQ660) are all CADs, this was the most stringent demonstration that not all CADs share these biological properties, and that lysosomal localization and specificity with respect to mechanism of action can be optimized through chemical modification. DQ661 is the first example of a lysosome-targeted agent that can mechanistically inhibit mTORC1 in the context of nutrient-rich conditions via disruption of mTOR. One previous study demonstrated that CADs as well as lysosome deacidifying agents possess anti-mTORC1 activity specifically due to lysosome impairment (43) . The compounds interrogated in that study included siramesine, concanamycin A, bafilomycin A and ammonium chloride. Siramesine inhibits lysosome function by inhibiting acid sphingomyelinase (ASM) (22) . However no connection between mTORC1 signaling and ASM inhibition was made in this previous report, and our data indicates that siramesine in nutrient-replete conditions cannot break the mTOR-Rheb interaction in the same manner as DQ661. Targeting mTORC1, which is constitutively activated in >70% of all cancers, with small molecule inhibitors remains a challenge due to limited efficacy and the onset of resistance and toxicity (7, 45) . Acquired resistance mechanisms to existing mTOR inhibitors include mTOR mutations. A third-generation mTOR inhibitor, RapaLink-1, can overcome these acquired resistance mechanisms (46) . However, lysosome-dependent catabolic programs such as autophagy and macropinocytosis represent mutationindependent adaptive resistance mechanisms to mTOR inhibition (12) (24) . By targeting PPT1, DQ661 concurrently inactivates mTORC1 function and overcomes these adaptive resistance mechanisms. Electron Microscopy. Electron microscopy was performed as previously described (48).
Deacidification of the lysosome with concanamycin A, baf and NH
Immunoblotting, lysosome fractionation and fluorescence microscopy. Immunoblotting was performed on whole-cell lysates, lysosomal extracts as previously described (11) .
Cell Signaling Technology antibodies: Rheb (#13879), β-actin (#3700), 4E-BP1 (#9644), phospho-4E-BP1 S65 (#13443), S6K (#2708), phospho-S6K T389 (#9206), S6 (#2317), phospho-S6 S240_S244 (#5364), p18 (#8975), RagA (#4357), RagC (#3360), mTOR (#2983), ATG5 (#2630), Cathepsin D (#2284), Caspase-7 (#12827) and phospho-H2AX (#9718). Galectin-3. LAMP2 was purchased from Santa Cruz. LC3B antibody was generated as described previously (48) . Lysosomal and extra-lysosomal fractions were purified according to the manufacturer's instructions (Sigma #LYSISO1).
PLA. PLA (Sigma #DUO92008) was performed as previously described (48).
MTT assay, and clonogenic assay. For MTT assays, cells were plated in 96-well plates (2,000 cells/well), allowed to adhere overnight, and treated. The clonogenic assay was performed as previously described (49) . Briefly, cells were suspended in appropriate culture media, and plated in 6-well plates (2 x 10 3 cells/well). Medium was changed with fresh drug every 3-4 days for 2 weeks. Colonies were stained with crystal violet and quantified.
RPPA and analysis methods. RPPA was conducted as previously described (50) . Macropinocytosis experiments. KPC pancreatic cancer cells plated (100,000 cells/well) upon glass cover slips and cultured in DMEM media containing 10% dialyzed FBS (Gemini Bio-Products), 0.2 mM glutamine (0.2Q) and 2% albumin (0.2Q + Alb). To measure macropinocytic uptake and lysosomal catabolism of ingested protein, cells were either fed BSA-647 (Thermo Fisher Scientific A34785) or DQ-BSA (Thermo Fisher Scientific D12051) for 3 hours. Cells were subsequently washed 4 times with cold PBS, fixed with 4% paraformaldehyde. KRPC cells were cultured for 5 doublings in DMEM containing fully 13 C-labeled essential histidine, lysine, phenylalanine, threonine, tyrosine, and valine, such that intracellular protein and AAs in the resulting cells were mostly labeled. After one PBS wash, these cells were switched to AA-free medium supplemented with 5% unlabeled BSA. Excretion of unlabeled AAs into the medium was monitored after 8 hours. AAs were extracted from the medium and subjected to LC-MS analysis as described previously (51) .
Fluorimetry. Small molecule fluorescent properties were observed on a Tecan M1000 fluorescent plate reader. UV-Vis spectroscopy was collected in triplicate and 420 nm was found to be the average most red shifted absorption across the library of dimeric quinacrines. Emission spectra were collected at 1 uM, which was confirmed to be in the PPT1 and Cathepsin D Enzyme assays: PPT1 enzymatic activity was measured as previously described (54) . Cathepsin D enzyme assay was performed according to the manufacturer's instructions (Abcam ab65302). In vivo mouse studies. NOD-scid gamma (NSG) mice (Jackson Laboratory) were used for xenograft studies. Tumor generation, tumor measurement and tumor harvesting performed as previously described (48). For the pancreatic cancer model, 2 x 10 6 G43 cells were subcutaneously injected with an equal volume of matrigel (BD) over the right flank of C57BL/6 mice (Jackson Laboratory) and tumors were treated when they became palpable. Tumors were measured using electronic calipers and volume was calculated as L x W 2 x 0.5. Tumor harvesting procedure and immunohistochemistry and EM were performed as previously described (48 the difference of the tumor growth trends among treatment groups. A P value less than 0.05 was considered as significantly different from the null hypothesis. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Figure Legends
Author Manuscript Published OnlineFirst on September 12, 2017; DOI: 10.1158/2159-8290.CD-17-0741 mTOR/LAMP2 localization. Below each panel is the respective co-localization analysis. Data are represented as mean ± SD. N = 50 cells per condition (ANOVA with Dunnett's multiple comparison test). *p<0.0001 versus Untreated group. (G) A375P cells were treated with DQ661 (6 hr, 3 μM) and lysosome fractions were isolated and immunoblotted. (H) A375P cells were treated with DQ661 (3 hr, 3 μM) and PLA was performed. Blue represents DAPI and red fluorescence represents mTOR-RagC interactions. (I) HEK293T cells expressing FLAG-RagB were treated with DQ661 (4 hr, 3 μM) and immunoprecipitation lysates were probed for mTOR. (J) PLA was performed on A375P cells were treated with rapamycin (3 μM), torin-1 (3 μM), baf (100 nM), siramesine (8 μM), or DQ661 (1 μM) for 3 hr. Blue is DAPI and red fluorescence reflects mTOR-Rheb interaction. (K) A375P cells were treated with HDSF (6 hr, 40 μM) and membrane fractions were isolated and immunoblotted. (L) A375P cells were treated with NT or PPT1 siRNA for 24 hours. Membranes were subsequently fractionated and immunoblotted. 
